ES2506665T3 - Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos - Google Patents

Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos Download PDF

Info

Publication number
ES2506665T3
ES2506665T3 ES09009972.2T ES09009972T ES2506665T3 ES 2506665 T3 ES2506665 T3 ES 2506665T3 ES 09009972 T ES09009972 T ES 09009972T ES 2506665 T3 ES2506665 T3 ES 2506665T3
Authority
ES
Spain
Prior art keywords
polypeptides
expressed
ligand
receptor
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES09009972.2T
Other languages
English (en)
Spanish (es)
Inventor
Jian Chen
Ellen Filvaroff
Sherman Fong
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Hanzhong Li
Kenneth J. Hillan
Daniel Tumas
Menno Van Lookeren
Richard L. Vandlen
Colin K. Watanabe
P. Mickey Williams
William I. Wood
Daniel G. Yansura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/031274 external-priority patent/WO2000053752A2/en
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/en
Priority claimed from PCT/US2000/005841 external-priority patent/WO2000053758A2/en
Priority claimed from PCT/US2000/007532 external-priority patent/WO2000070050A1/en
Priority claimed from PCT/US2000/015264 external-priority patent/WO2000073452A2/en
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/030873 external-priority patent/WO2001040465A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES2506665T3 publication Critical patent/ES2506665T3/es
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
ES09009972.2T 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos Expired - Lifetime ES2506665T3 (es)

Applications Claiming Priority (30)

Application Number Priority Date Filing Date Title
US17209699P 1999-12-23 1999-12-23
US172096P 1999-12-23
WOPCT/US99/31274 1999-12-30
PCT/US1999/031274 WO2000053752A2 (en) 1999-03-08 1999-12-30 Promotion or inhibition of angiogenesis and cardiovascularization
US17548100P 2000-01-11 2000-01-11
US175481P 2000-01-11
PCT/US2000/004341 WO2000053756A2 (en) 1999-03-08 2000-02-18 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US00/04341 2000-02-18
PCT/US2000/005841 WO2000053758A2 (en) 1999-03-08 2000-03-02 Compositions and methods for the treatment of immune related diseases
WOPCT/US00/05841 2000-03-02
US19100700P 2000-03-21 2000-03-21
WOPCT/US00/07532 2000-03-21
PCT/US2000/007532 WO2000070050A1 (en) 1999-05-14 2000-03-21 Compositions and methods for the treatment of immune related diseases
US191007P 2000-03-21
WOPCT/US00/15264 2000-06-02
PCT/US2000/015264 WO2000073452A2 (en) 1999-06-02 2000-06-02 Compositions and methods for the treatment of immune related diseases
US21380700P 2000-06-22 2000-06-22
US213807P 2000-06-22
US64484800A 2000-08-22 2000-08-22
US664848 2000-08-22
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
WOPCT/US00/23328 2000-08-24
US24283700P 2000-10-24 2000-10-24
US242837P 2000-10-24
PCT/US2000/030873 WO2001040465A2 (en) 1999-11-30 2000-11-10 Compositions and methods for the treatment of immune related diseases
WOPCT/US00/30873 2000-11-10
US25364600P 2000-11-28 2000-11-28
US253646P 2000-11-28
WOPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same

Publications (1)

Publication Number Publication Date
ES2506665T3 true ES2506665T3 (es) 2014-10-13

Family

ID=40140243

Family Applications (7)

Application Number Title Priority Date Filing Date
ES09009972.2T Expired - Lifetime ES2506665T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos
ES07016903T Expired - Lifetime ES2380812T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES07016901T Expired - Lifetime ES2380958T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos
ES10009491.1T Expired - Lifetime ES2458349T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES07016902T Expired - Lifetime ES2388748T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES00989401T Expired - Lifetime ES2333772T3 (es) 1999-12-23 2000-12-20 Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
ES07016899T Expired - Lifetime ES2379101T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos

Family Applications After (6)

Application Number Title Priority Date Filing Date
ES07016903T Expired - Lifetime ES2380812T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES07016901T Expired - Lifetime ES2380958T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y utilizaciones terapéuticas de los mismos
ES10009491.1T Expired - Lifetime ES2458349T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos
ES07016902T Expired - Lifetime ES2388748T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos a IL-17 y usos terapéuticos de los mismos
ES00989401T Expired - Lifetime ES2333772T3 (es) 1999-12-23 2000-12-20 Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
ES07016899T Expired - Lifetime ES2379101T3 (es) 1999-12-23 2000-12-20 Polipéptidos homólogos IL-17 y usos terapéuticos de los mismos

Country Status (10)

Country Link
EP (1) EP1240325B1 (enExample)
JP (10) JP5070117B2 (enExample)
AT (5) ATE519847T1 (enExample)
AU (1) AU2590901A (enExample)
CA (1) CA2391374A1 (enExample)
CY (1) CY1112334T1 (enExample)
DK (1) DK1240325T3 (enExample)
ES (7) ES2506665T3 (enExample)
PT (4) PT1897944E (enExample)
WO (1) WO2001046420A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
JP3577586B2 (ja) 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
AU2001241816A1 (en) * 2000-02-29 2001-09-12 Zymogenetics Inc. Methods for promoting production of myelin by schwann cells
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
CA2406245A1 (en) * 2000-04-18 2001-10-25 Schering Corporation Il-174 uses, compositions and methods
CA2410083A1 (en) * 2000-05-24 2001-11-29 Schering Corporation Mammalian receptor proteins; related reagents and methods
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008259A2 (en) * 2000-07-26 2002-01-31 Zymogenetics, Inc. Human cytokine receptor
EP1529843A3 (en) * 2000-08-11 2005-06-08 Eli Lilly & Company Novel secreted proteins and their uses
WO2002033083A2 (en) * 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
AU2002225714A1 (en) * 2000-11-10 2002-05-21 The Regents Of The University Of California Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2461665A1 (en) * 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
WO2004024076A2 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2004047728A2 (en) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2008500009A (ja) * 2003-03-03 2008-01-10 ジェネンテック・インコーポレーテッド 全身性エリテマトーデスの治療のための組成物と方法
ES2424353T3 (es) * 2003-07-08 2013-10-01 Genentech, Inc. Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
AU2004292393C1 (en) 2003-11-21 2011-08-04 Ucb Pharma S.A. Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
WO2005108616A1 (en) 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AU2005254998B2 (en) 2004-06-10 2011-10-27 Zymogenetics, Inc. Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation
JP2008513415A (ja) * 2004-09-21 2008-05-01 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 神経疾患の治療および予防のためのｉｌ−１７ｆの使用
WO2007019453A2 (en) * 2005-08-04 2007-02-15 Zymogenetics, Inc. Treatment of wounds using il-17b
US20070249533A1 (en) 2005-09-28 2007-10-25 Levin Steven D Il-17a and il-17f antagonists and methods of using the same
EP1987058B1 (en) 2006-02-10 2010-05-12 ZymoGenetics, Inc. Soluble il-17rcx4 and methods of using in inflammation
CN101553501A (zh) 2006-10-26 2009-10-07 诺沃-诺迪斯克有限公司 Il-21变种
EP2089050A2 (en) * 2006-11-08 2009-08-19 Zymogenetics, Inc. Il- 17b for use in wound healing
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
US20120107267A1 (en) 2009-03-11 2012-05-03 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
US8137671B2 (en) 2009-05-05 2012-03-20 Genentech, Inc. Anti-IL-17F antibodies
WO2010142551A2 (en) * 2009-06-12 2010-12-16 Ablynx N.V. Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
EP2665750A1 (en) 2011-01-17 2013-11-27 Novo Nordisk A/S Il-21 ligands
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
HUE037087T2 (hu) * 2011-10-19 2018-08-28 Morphosys Ag IL17C antagonistái gyulladásos rendellenességek kezelésére
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
KR20150050921A (ko) * 2013-11-01 2015-05-11 현대중공업 주식회사 폐열 회수용 연관식 보일러
JP2017537891A (ja) 2014-10-31 2017-12-21 ジェネンテック， インコーポレイテッド 抗ｉｌ−１７ａ及びｉｌ−１７ｆ交差反応性抗体変異体、ならびにそれらを含む組成物、それらを作製する方法、及び使用する方法
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
WO2000070050A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
BR9809778A (pt) * 1997-04-25 2000-06-20 Zymogenetics Inc Polinucleotìdeo isolado, vetor de expressão, peptìdeo ou polipetìdeo isolado, anticorpo, processo para produzir o mesmo, fragmentos de anticorpos, anticorpos de cadeia única ou anticorpos humanizados, e, anticorpo anti-idiotìpico.
WO1999003982A1 (en) * 1997-07-16 1999-01-28 Human Genome Sciences, Inc. Interleukin-20
AU9482498A (en) * 1997-09-17 1999-04-05 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
WO1999032632A1 (en) * 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
EP1490386B1 (en) * 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
JP3577586B2 (ja) * 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
AU3207000A (en) * 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
PT1141297E (pt) * 1999-01-11 2010-01-06 Schering Corp Citoquinas de mamíferos relacionadas com a interleucina-17. polinucleótidos que as codificam. utilizações
AU2596700A (en) * 1999-03-08 2000-09-28 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
ES2286029T3 (es) * 1999-07-07 2007-12-01 Zymogenetics Inc Receptor de citocina humano.
JP2003527104A (ja) * 1999-12-23 2003-09-16 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療上の用途

Also Published As

Publication number Publication date
WO2001046420A3 (en) 2002-05-10
ES2458349T3 (es) 2014-05-05
ES2388748T3 (es) 2012-10-18
JP2014239685A (ja) 2014-12-25
HK1114636A1 (en) 2008-11-07
ATE519847T1 (de) 2011-08-15
EP1240325A2 (en) 2002-09-18
ES2333772T3 (es) 2010-03-01
HK1114635A1 (en) 2008-11-07
HK1114638A1 (en) 2008-11-07
PT1897947E (pt) 2012-03-29
WO2001046420A2 (en) 2001-06-28
JP2015007091A (ja) 2015-01-15
HK1114637A1 (en) 2008-11-07
ES2379101T3 (es) 2012-04-20
JP2010266454A (ja) 2010-11-25
PT1240325E (pt) 2010-01-07
PT1897944E (pt) 2011-11-28
JP5070117B2 (ja) 2012-11-07
PT1897945E (pt) 2012-03-29
HK1150856A1 (en) 2012-01-13
WO2001046420A8 (en) 2002-07-04
JP2008278887A (ja) 2008-11-20
JP5258691B2 (ja) 2013-08-07
JP2009278996A (ja) 2009-12-03
DK1240325T3 (da) 2010-01-25
CY1112334T1 (el) 2015-12-09
ATE541930T1 (de) 2012-02-15
JP2009159968A (ja) 2009-07-23
JP2013165712A (ja) 2013-08-29
JP2015077137A (ja) 2015-04-23
JP2012152218A (ja) 2012-08-16
ATE537258T1 (de) 2011-12-15
JP2012115275A (ja) 2012-06-21
CA2391374A1 (en) 2001-06-28
ATE541931T1 (de) 2012-02-15
ES2380958T3 (es) 2012-05-21
EP1240325B1 (en) 2009-09-30
HK1114634A1 (en) 2008-11-07
ATE444361T1 (de) 2009-10-15
AU2590901A (en) 2001-07-03
ES2380812T3 (es) 2012-05-18

Similar Documents

Publication Publication Date Title
ES2506665T3 (es) Polipéptidos homólogos IL-17 e IL-17R y usos terapéuticos de los mismos
ES2618785T3 (es) Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos
Tanaka et al. Expression of p21 ras oncoproteins in human cancers
ES2289780T3 (es) Dos receptores acoplados a proteina g humanos: gpcr 2 inducido por ebv (ebi-2) y gpcr de tipo edg-1.
Sun et al. Topography of ribosomal proteins of the Escherichia coli 30S subunit as studied with reversible cross-linking reagent methyl 4-mercaptobutyrimidate
ES2212533T3 (es) Uso de folistatina para la fabricacion de un medicamento para el tratamiento de trastornos relacionados con los musculos.
ES2582208T3 (es) Marcador molecular para células madre cancerosas
DE69837104D1 (de) An g-protein gekoppelte rezeptoren und deren verwendungen
US9498510B2 (en) Polypeptide, nucleotide sequence thereof, and method for using the same for preventing DNA synthesis and inhibiting cell proliferation
ES2276531T3 (es) Gen ly6h.
ES2424976T3 (es) Isoformas relativas al cáncer de componentes de complejos de factores de transcripción como biomarcadores y dianas de fármacos
CN108715616A (zh) 靶向人源化间皮素的嵌合抗原受体方法和用途
ES2242195T3 (es) Moduladores de proteinas reguladoras.
CN112358531B (zh) 靶向her2蛋白的多肽及其应用
ES2342713T3 (es) Caracterizacion de moleculas.
Chaturvedi et al. The P-loop region of Schlafen 3 acts within the cytosol to induce differentiation of human Caco-2 intestinal epithelial cells
MXPA05012546A (es) Materiales y metodos que se relacionan con los oligomeros receptores acoplados a la proteina g.
US20230086188A1 (en) Proteins with predictable liquid-liquid phase separation
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
WO1998016557A1 (en) Assays for g-protein-linked receptors
ES2659877T3 (es) Un gen que codifica un homólogo de glicoproteína p humana multifármaco-resistente en el cromosoma 7p15-21 y usos del mismo
ES2397327T3 (es) Compuestos asociados a un dominio único de TDF y análogos de los mismos
JPH1118786A (ja) 腫瘍壊死関連受容体ｔｒ７
ES2401233T3 (es) Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR
ATE313647T1 (de) Dickdarm spezifische gene und proteine